Medical devices, healthcare technology and the business of care
COMPANY INTELLIGENCE

Nyxoah S.A.

Explore this company’s associated devices, FDA decisions and regulatory history.

Clinical monitoring equipment, editorial photography

Nyxoah S.A.

Regulatory records
5
Linked recall entries
0
Headquarters
Not reported
Brand website
Not reported
COMPANY INTELLIGENCE

What the linked records show

MedtechLedger currently links 5 FDA records to the applicant name Nyxoah S.A.. It includes 1 original PMA approval. 4 entries are PMA supplements. These are records held by this publication, rather than a count of the company’s entire portfolio.

The dated entries run from Aug 8, 2025 to Jul 30, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.

Product code MNQ appears in 5 of the 5 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.

The largest PMA family in this collection is P240024, with 5 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.

Applicant mailing address recorded by FDA: Rue Edouard Belin, 12, Mont-Saint-Guibert, 1435. Recorded on P240024/S004, decision dated Jul 30, 2026.

Changes described in PMA records

P240024/S004: Genio System 2.1

FDA’s recorded scope: Approval for firmware updates to the Activation Chip (AC) Model #2364 of the Genio System 2.1 with associated updates to software documentation, risk management files, and verification and validation reports.

Jul 30, 2026 · Real-Time Process

P240024/S003: Genio System 2.1

FDA’s recorded scope: Approval for the discontinuation of the External Stimulator (ES) and its removal from the surgical implantation workflow for the Genio System 2.1, with associated updates to the Surgeon Manuals.

Jun 8, 2026 · Real-Time Process

P240024/S002: Genio System 2.1

FDA’s recorded scope: approval of the protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P240024.

Nov 6, 2025 · Normal 180 Day Track No User Fee

P240024/S001: Genio System 2.1

FDA’s recorded scope: approval of the Post Approval Study protocol for the New Enrollment Study (BREATHE Study)

Oct 3, 2025 · Normal 180 Day Track No User Fee

P240024: Genio System 2.1

FDA’s recorded scope: Approval for The Nyxoah Genio System 2.1, which includes the Implantable Stimulator Model #2954, Surgical Template, External Stimulator, Disposable Patch, Activation Chip Model #2364, Charging Unit Model #2238, Sleep Lab Application, Repeater, and Smartphone Application. It is indicated for use in the treatment of moderate to severe Obstructive Sleep Apnea (OSA) (apnea-hypopnea index [AHI] of greater than or equal to 15 and less than or equal to 65). The device is intended for adult patients 22 years of age and older who have been confirmed to fail, cannot tolerate or are ineligible to be treated with current standard of care treatments including lifestyle modifications, positive airway pressure (PAP) treatments (such as continuous positive airway pressure [CPAP] or bi-level positive airway pressure [BiPAP] machines), oral appliances (such as mandibular advancement devices), and pharmacotherapy (such as tirzepatide). PAP failure is defined as an inability to eliminate OSA (residual AHI of greater than 15 despite PAP usage), and PAP intolerance is defined as: 1. Inability to use PAP (at least 5 nights per week of usage; usage defined as greater than 4 hours of use per night), or 2. Unwillingness to use PAP (PAP therapy initiated and subsequently discontinued by choice).

Aug 8, 2025

Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.

Regulatory record history

  1. Genio System 2.1

    P240024/S004 · PMA supplement
  2. Genio System 2.1

    P240024/S003 · PMA supplement
  3. Genio System 2.1

    P240024/S002 · PMA supplement
  4. Genio System 2.1

    P240024/S001 · PMA supplement
  5. Genio System 2.1

    P240024 · PMA decision
Source information

Source updated Nov 9, 2026. Retrieved Nov 21, 2026.